Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: A double-blind, placebo-controlled study

European Neuropsychopharmacology

Volumn 15, Issue 1, 2005, Pages 69-74

  Erzegovesi, Stefano ^a   Guglielmo, Emanuela ^a   Siliprandi, Francesca ^a   Bellodi, Laura ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Fluvoxamine; Obsessive compulsive disorder; Risperidone; Serotonin

Indexed keywords

FLUVOXAMINE; PLACEBO; RISPERIDONE;

ADULT; AGED; APPETITE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HUMAN; ITALY; LOW DRUG DOSE; MALE; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RATING SCALE; SEDATION; SIDE EFFECT; STANDARDIZATION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 9644302676     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.04.004     Document Type: Article

References (45)

1. Alarcon R.D., Libb J.W., Spitler D. A predictive study of obsessive compulsive response to clomipramine. J. Clin. Psychopharmacol. 13:1993;210-213
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. fourth ed.:1994;APA Press, Washington, DC. DSM IV
3. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251
4. Barr L.C., Goodman W.K., Price L.H., et al. The serotonin hypothesis of obsessive compulsive disorder: implication of pharmacologic challenge studies. J. Clin. Psychiatry. 53(Suppl. 4):1992;17-28
5. Bogetto F., Bellino S., Vaschetto P., et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 96(2):2000;91-98
6. Bogetto F., Albert U., Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur. Neuropsychopharmacol. 12(3):2002;181-186
7. DeVane C.L., Nemeroff C.B. An evaluation of risperidone drug interactions. J. Clin. Psychopharmacol. 21(4):2001;408-416
8. Erzegovesi S., Cavallini M.C., Cavedini P., et al. Clinical predictors of drugs response in obsessive-compulsive disorder. J. Clin. Psychopharmacol. 21(5):2001;272-275
9. Fineberg N.A., Bullock D.B., Montgomery S.A. Serotonin reuptake inhibitors are the treatment of choice in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 7(Suppl. 1):1992;43-47
10. Giakas W.J. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder (Letter). Am. J. Psychiatry. 152:1995;157
11. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use and reliability. Arch. Gen. Psychiatry. 46:1989;1006-1011
12. Greist J.H., Jefferson J.W., Kobac K.A., et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder. Arch. Gen. Psychiatry. 52:1995;53-60
13. Guy W. ECDEU Assessment Manual For Psychopharmacology. 3rd ed.:1976;National Institute of Mental Health Ed, Rockville
14. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62
15. Hollander E., Bienstock C.A., Koran L.M., et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry. 63(Suppl. 6):2002;20-29
16. Jacobsen F.M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J. Clin. Psychiatry. 56:1995;423-429
17. Jenike M.A., Hyman S., Baer L., et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implication for a serotoninergic theory. Am. J. Psychiatry. 147:1990;1209-1215
18. Koran L.M., Ringold A.L., Elliott M.A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry. 61(7):2000;514-517
19. Liebowitz M.R., Turner S.M., Piacentini J., et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J. Am. Acad. Child Adolesc. Psych. 41(12):2002;1431-1438
20. Lombroso P.J., Scanhill L., King R.A., et al. Risperidone treatment of children and adolescents with chronic tic disorder: a preliminary report. J. Am. Acad. Child Adolesc. Psych. 34:1995;1147-1152
21. Mattes J. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 1:1986;170-173
22. McDougle C.J., Goodman W.K., Price L.H., et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am. J. Psychiatry. 147:1990;652-654
23. McDougle C.J., Price L.H., Goodman W.K., et al. A controlled clinical trial of lithium augmentation in fluvoxamine refractory obsessive compulsive disorder: lack of efficacy. J. Clin. Psychopharmacol. 11:1991;175-184
24. McDougle C.J., Goodman W.K., Leckman J.F., et al. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry. 51:1994;302-308
25. McDougle C.J., Fleishmann R.L., Epperson C.N., et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J. Clin. Psychiatry. 56(11):1995;526-528
26. McDougle C.J., Epperson C.N., Pelton G.H., et al. A double-blind, placebo-controlled study of risperidone addition in serotonin inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry. 57(8):2000;794-801
27. Montgomery S.A., Kasper S., Stein D.J., Bang Hedegaard K., Lemming O.M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 16(2):2001;75-86
28. Mundo E., Bareggi S.R., Pirola R., et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J. Clin. Psychopharmacol. 17(1):1997;4-10
29. Mundo E., Guglielmo E., Bellodi L. Effect of adjuvant pindolol on the antiosessional response to fluvoxamine: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 13:1998;219-224
30. Murphy D.L., Pickar D., Alterman I.S. Methods for evaluation of depressive and manic behavior. Burdock E.L., Studilovsky A., Gershon S. The Behavior of Psychiatric Patients. 1982;355-392 Marcel Dekker, New York
31. Pigott T.A., Pato M.T., L'Heureux F., et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine treated patients with obsessive compulsive disorder. J. Clin. Psychopharmacol. 11:1991;242-248
32. Pigott T.A., L'Heureux F., Hill J.L., et al. A double blind study of adjuvant buspirone hydrochloride in clomipramine treated patients with obsessive compulsive disorder. J. Clin. Psychopharmacol. 12:1992;11-18
33. Ravizza L., Barzega G., Bellino S., et al. Predictors of drug treatment response in obsessive-compulsive disorder. J. Clin. Psychiatry. 56(8):1995;368-373
34. Ravizza L., Barzega G., Bellino S., et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder. Psychopharmacol. Bull. 32(4):1996;677-682
35. Robins L., Heltzer J.E., Cottler L. NIMH Diagnostic Interview Schedule. Version III-R (DIS-R). 1989;Washington Univ. School Of Medicine, St. Louis, MO
36. Saxena S., Wang D., Bystritsky A., et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry. 57(7):1996;303-306
37. Smeraldi E., Erzegovesi S., Bianchi I., et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a preliminary study. New Trends Exp. Clin. Psychiatry. 8:1992;63-65
38. Statistica for Windows Release 4.5. 1993;Statsoft, Tulsa, OK
39. Stein D.J., Bouwer C., Hawkridge S., et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry. 58(3):1997;119-122
40. Thoren P., Asberg M., Cronholm B. Clomipramine treatment of obsessive-compulsive disorder. A controlled clinical trial. Arch. Gen. Psychiatry. 37:1980;1281-1285
41. Todorov C., Freeston M.H., Borgeat F. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible? Can. J. Psychiatry. 45(3):2000;257-262
42. Tollefson G.D., Rampey A.H. Jr., Potvin J.H., et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry. 51(7):1994;559-567
43. Yasui-Furukori N., Hidestrand M., Spina E., et al. Different enantioselective 9-hydroxilation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 29(10):2001;1263-1268
44. Zohar J., Mueller E.A., Insel T.R., et al. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry. 44(11):1987;946-951
45. Zohar J., Judge R. OCD Paroxetine Study Investigators Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry. 169:1996;468-474